Puridify, a London, UK-based newly formed company providing purification solutions for biotherapeutic manufacturing, raised £850k in funding.
The round was co-led by Imperial Innovations Group plc (AIM:IVO), the technology commercialization and investment company and S.R.One Ltd, GlaxoSmithKline’s venture captial fund, with participation from UCL Business PLC (UCLB).
The company, which received additional matched-funding awards totalling £780k from the UK’s innovation agency, the Technology Strategy Board, intends to use the funds to advance the technology.
Led by Oliver Hardick, CEO, Puridify is developing proprietary nanofibre technology to improve the efficiency of purification in biopharmaceutical production, allowing more drug product to be produced in a shorter amount of time and at lower cost.
The platofrm was developed in the Advanced Centre for Biochemical Engineering at UCL (University College London) and UCLB, the technology transfer office for UCL, licensed this technology to Puridify in 2014.